Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

0.6749 -0.0251 (-3.59%)
Streaming Delayed Price Updated: 10:04 AM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
InMed Pharmaceuticals (INM): Acquiring BayMedica
LONDON, UK / ACCESSWIRE / September 20, 2021 / InMed has announced that it has entered into a definitive agreement to acquire BayMedica, a private US-based company that is focusing on the manufacture... 
From Edison Investment Research Limited
Via AccessWire
News headline image
The Week In Cannabis: FDA, CDC, Delta-8 THC, WADA, Canopy, Sundial, Canada, LatAm And More ↗
Below is a recap of the main news related to the cannabis industry and markets for the week of September 13, 2021. 
Via Benzinga
Topics Cannabis
News headline image
9 Cannabis Stocks Lighting Up The News Cycle ↗
Canopy Growth and Sundial both launched groundbreaking new products. 
Via Talk Markets
Topics Cannabis
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids ↗
Establishes leadership position in manufacturing and commercialization of rare cannabinoids Positions InMed within large and gro... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities
Via CannabisNewsWire
News headline image
Video: All You Need To Know About Leafly And Its IPO, COO Sam Martin Shares Details On The Co., Upcoming Stock Listing ↗
Benzinga’s 
Via Benzinga
Topics Initial Public Offering
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters Definitive Agreement for ‘Transformative’ Acquisition of Leading Manufacturer of Rare Cannabinoids
Via CannabisNewsWire
News headline image
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
News headline image
InMed Pharmaceuticals To Acquire BayMedica, Rare Cannabinoid Manufacturer, For ~$3.66M ↗
InMed Pharmaceuticals (NASDAQ: INM) announced on Monday that it has entered into a definitive agreement to acquire BayMedica Inc., a private company that ... 
Via Benzinga
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Slated for Live Webcast at VirtualInvestorConferences.com
Via CannabisNewsWire
InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference
Via CannabisNewsWire
Topics Cannabis
News headline image
InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production Of Rare Cannabinoids At Pharmaceutical Levels ↗
Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoids InMed Pharmaceutical has developed a... 
Via Benzinga
InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright Ophthalmology Virtual Conference
Via CannabisNewsWire
InMed Pharmaceuticals Inc. (NASDAQ: INM) and Its Quest to Build an Industry-Leading, Rare Cannabinoid Enterprise
Via CannabisNewsWire
News headline image
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
420 with CNW — Patients with High-Grade Gliomas Register Improved Quality of Life after Using Medical Marijuana
Via CannabisNewsWire
Topics Cannabis
News headline image
88 Biggest Movers From Yesterday ↗
Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated... 
Via Benzinga
News headline image
InMed set to Become Major Player in Manufacturing of Rare Cannabinoids ↗
Image from Shutterstock. When it comes to producing rare cannabinoids, the proof is in the process. Rare cannabinoids, compounds found in cannabis, have been shown to be... 
Via Benzinga
Topics Cannabis
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Continues Optimization of IntegraSyn(TM) to Increase Cannabinoid Yield
Via CannabisNewsWire
News headline image
The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 20) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
Before 10 a.m. ET Thursday, 8 stocks made new 52-week lows. Areas of Interest: The largest company in terms of market cap to set a new 52-week low was Enel Chile (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Alterity Therapeutics (NASDAQ:ATHE) stock rose 23.16% to $1.54 during Wednesday's pre-market session. The company's market cap stands at $53.4 million.... 
Via Benzinga
News headline image
77 Biggest Movers From Yesterday ↗
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52. Repro Med Systems, Inc... 
Via Benzinga
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) shares jumped 104.2% to close at $8.70 on Monday after the company announced the full details of its Phase 2 trial... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.